Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matt Westfall

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|January 10, 2013
Single cell network profiling assay in bladder cancerTodd M Covey, Manish A Vira, Matt Westfall, et al.
The Lancet. Gastroenterology & Hepatology|November 16, 2025
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trialVipul Jairath, Silvio Danese, Geert R D'Haens, et al.
British Journal of Haematology|May 21, 2013
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology GroupNorman J Lacayo, Todd A Alonzo, Urte Gayko, et al.
Plos One|April 18, 2015
Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemiaAlessandra Cesano, Cheryl L Willman, Kenneth J Kopecky, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|January 10, 2013
Single cell network profiling assay in bladder cancerTodd M Covey, Manish A Vira, Matt Westfall, et al.
The Lancet. Gastroenterology & Hepatology|November 16, 2025
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trialVipul Jairath, Silvio Danese, Geert R D'Haens, et al.
British Journal of Haematology|May 21, 2013
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology GroupNorman J Lacayo, Todd A Alonzo, Urte Gayko, et al.
Plos One|April 18, 2015
Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemiaAlessandra Cesano, Cheryl L Willman, Kenneth J Kopecky, et al.
Pageof 1